RILPIVIRIN - nový nenukleosidový inhibitor reverzní transkriptázy HIV-1

Title in English RILPIVIRINE - a novel HIV-i non-nucleoside reverse transcriptase inhibitor
Authors

SNOPKOVÁ Svatava HAVLÍČKOVÁ Kateřina POLÁK Pavel ŠLESINGER Pavel HUSA Petr

Year of publication 2013
Type Article in Periodical
Magazine / Source Klinická mikrobiologie a infekční lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Epidemiology, infectious diseases and clinical immunology
Keywords Rilpivirin; non-nucleoside reverse transcriplase inhibitors; diarylpyrimidine inhibitors; HIV; antiretroviral therapy
Description The arlicle summarizes the basic facts about the pharmacokinetic profile, metabolism and drug interactions of rilpivirine (RPV). This is the latest orally administered second-generation non-nucleoside reverse transcriplase inhibitor (NNRTI) for antiretroviral-naive patients with HIV-1 infection. Conformational flexibility and adaptability are the factors that dominantly determine the high resistance barrier of RPV and are the unique features of diarylpyrimidine inbibitors (DAPY inhibitors - 2nd-generation NNRTIs). Multicentre studies ECHO and THRIVE are also reviewed. Current guidelines for the treatment of HIV/AIDS are mentioned as well as the role of RPV in current therapeutic regiments.

You are running an old browser version. We recommend updating your browser to its latest version.

More info